High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension

Circulation: Heart Failure

Volumn 7, Issue 1, 2014, Pages 116-122

  Robbins, Ivan M ^a   Hemnes, Anna R ^a   Pugh, Meredith E ^a   Brittain, Evan L ^a   Zhao, David X ^b   Piana, Robert N ^a   Fong, Pete P ^a   Newman, John H ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Hemodynamics; Hypertension, pulmonary; Pulmonary arterial hypertension; Pulmonary heart disease

Indexed keywords

SODIUM CHLORIDE;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART CATHETERIZATION; HEART OUTPUT; HUMAN; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCCULT PULMONARY VENOUS HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

HEMODYNAMICS; HYPERTENSION, PULMONARY; PULMONARY ARTERIAL HYPERTENSION; PULMONARY HEART DISEASE;

ADULT; AGED; CARDIAC CATHETERIZATION; COHORT STUDIES; DEHYDRATION; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; FLUID THERAPY; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PREVALENCE; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84896116982     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000468     Document Type: Article

References (23)

1. Hatano S, Strasser T. Eds. Primary Pulmonary Hypertension: Report on a WHO Meeting. Geneva: World Health Organization;1975:7-45.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
3. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30:2493-2537.
4. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
5. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF; EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-354.
6. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology. 2008;109:273-280.
7. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O?Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005;150:46-53.
8. Bush CA, Stang JM, Wooley CF, Kilman JW. Occult constrictive pericardial disease. Diagnosis by rapid volume expansion and correction by pericardiectomy. Circulation. 1977;56:924-930.
9. Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS, Carrick-Ranson G, Levine BD. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127:55-62.
10. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M. High prevalence of occult left heart disease in scleroderma- pulmonary hypertension. Eur Respir J. 2013;42:1083-1091.
11. McGoon, D. Gutterman, V. Steen Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest. 126; 2004:14S-34S.
12. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685-692.
13. Jaïs X, D?Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127-2134.
14. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009;136:31-36.
15. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res. 1970;4:23-30.
16. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595.
17. Pugh ME, Hemnes AR, Newman JH, Robbins IM. Treatment of Non- Group 1 Pulmonary Hypertension: Results of a Survey of Pulmonary Hypertension Centers in the United States. J Heart Lung Transpl. 2012;31:S211 (abstract).
18. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, Maurer G, Lang IM. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in out-of-proportion pulmonary hypertension. Chest. 2013;143:758-766.
19. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, Armitage JM, Hardesty RL, Griffith BP. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J. 1993;126:896-904.
20. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, Rich S. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4:257-265.
21. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase- 5 inhibition in a 1-year study. Circulation. 2011;124:164-174.
22. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562.
23. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136:37-43.